Cargando…
A smarter way to manage asthma with a combination of a long-acting β(2)-agonist and inhaled corticosteroid
Symbicort SMART® (Symbicort Maintenance and Reliever Therapy) represents a new and unique way of treating patients with moderate-to-severe asthma, ie, those patients who require combination treatment with an inhaled corticosteroid and a long-acting inhaled β(2)-agonist. Symbicort SMART enables patie...
Autor principal: | Selroos, Olof |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936317/ https://www.ncbi.nlm.nih.gov/pubmed/18360644 |
Ejemplares similares
-
Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022) -
Impact of adherence to treatment with inhaled
corticosteroids/long-acting β-agonists on asthma outcomes in the United
States
por: Averell, Carlyne M., et al.
Publicado: (2022) -
RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008) -
Retraction Note to: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2009) -
Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)